MannKind Corp. (MNKD)

[Denise Chanterelle]

Early adopters are endorsing Afrezza as a superior new insulin, not only because it is inhaled, but more so because Afrezza is responsible for drastically improved A1C blood glucose levels. But those improved A1C numbers are directly connected to the fact that Afrezza is inhaled because Afrezza works much faster through the lungs than injected subcutaneous insulin through the skin, thus eliminating excessive blood glucose significantly more quickly.

Although early adopters appreciate the ease of use associated with the Afrezza inhaler, ultimately, it is the quality of the results that they achieve in using Afrezza that keep early adopters enthusiastic.